Mental Health Institute of the Second Xiangya Hospital, Key Laboratory of Psychiatry and Mental Health of Hunan Province, Central South University, Changsha, Hunan, People's Republic of China ; Department of Psychology, Guangzhou First People's Hospital, Guangzhou, Guangdong, People's Republic of China.
Mental Health Institute of the Second Xiangya Hospital, Key Laboratory of Psychiatry and Mental Health of Hunan Province, Central South University, Changsha, Hunan, People's Republic of China.
Neuropsychiatr Dis Treat. 2014 Jun 17;10:1103-11. doi: 10.2147/NDT.S64236. eCollection 2014.
Accumulating evidence suggests that neuroinflammation affecting microglia plays an important role in the etiology of schizophrenia, and appropriate control of microglial activation may be a promising therapeutic strategy for schizophrenia. Minocycline, a second-generation tetracycline that inhibits microglial activation, has been shown to have a neuroprotective effect in various models of neurodegenerative disease, including anti-inflammatory, antioxidant, and antiapoptotic properties, and an ability to modulate glutamate-induced excitotoxicity. Given that these mechanisms overlap with neuropathologic pathways, minocycline may have a potential role in the adjuvant treatment of schizophrenia, and improve its negative symptoms. Here, we review the relevant studies of minocycline, ranging from preclinical research to human clinical trials.
越来越多的证据表明，影响小胶质细胞的神经炎症在精神分裂症的发病机制中起着重要作用，适当控制小胶质细胞的激活可能是治疗精神分裂症的一种有前途的策略。米诺环素是一种抑制小胶质细胞激活的第二代四环素，已被证明在各种神经退行性疾病模型中具有神经保护作用，具有抗炎、抗氧化和抗细胞凋亡作用，并具有调节谷氨酸诱导的兴奋性毒性的能力。鉴于这些机制与神经病理学途径重叠，米诺环素可能在精神分裂症的辅助治疗中发挥作用，并改善其阴性症状。在这里，我们回顾了米诺环素的相关研究，从临床前研究到人体临床试验。
